Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 11/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239136 | 0.84 | LMNA (0.41) | ADRA1DADRA1AADRA1BBDKRB1PDE4A | |
| SCHEMBL26239138 | 0.84 | BDKRB1 (0.40) | ADRA1DADRA1AADRA1BBDKRB1PDE4A | |
| SCHEMBL26239140 | 0.83 | BDKRB1 (0.39) | ADRA1DADRA1AADRA1BBDKRB1PDE4A | |
| SCHEMBL26239143 | 0.82 | BDKRB1 (0.42) | ADRA1DADRA1AADRA1BBDKRB1PDE4A | |
| SCHEMBL26239133 | 0.81 | ADRA1D (0.49) | ADRA1DADRA1AADRA1BPDE4APDE4B | |
| SCHEMBL26239145 | 0.79 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BBDKRB1PDE4A | |
| SCHEMBL25388961 | 0.76 | LMNA (0.40) | ADRA1DADRA1AADRA1BLMNAGPR119 | |
| SCHEMBL26238713 | 0.74 | LMNA (0.42) | LMNAGPR119MC4R | |
| SCHEMBL25388886 | 0.72 | GPR119 (0.43) | BDKRB1GPR119 | |
| SCHEMBL25388967 | 0.71 | SMN1; SMN2 (0.47) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4472947-A1 | SWEETENER COMPOSITIONS | Firmenich Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172415-A1 | SWEETENER COMPOSITIONS | FIRMENICH INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250280861-A1 | SWEETENER COMPOSITIONS | GPR119, TAS2R50, TAS2R30 | ADRA1D 4209/4885ADRA1A 4335/4885ADRA1B 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.